These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1735886)

  • 1. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
    Miller CB; Platanias LC; Mills SR; Zahurak ML; Ratain MJ; Ettinger DS; Jones RJ
    J Natl Cancer Inst; 1992 Jan; 84(2):98-103. PubMed ID: 1735886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
    Mantovani G; Ghiani M; Curreli L; Maccio A; Massa D; Succu G; Lai P; Massa E; Mudu MC; Astara G
    Oncol Rep; 1999; 6(2):421-6. PubMed ID: 10023014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy.
    Pawlicki M; Jassem J; Bösze P; Lotan C; Kurteva GP; Siddiqui M; Kosmidis PA; Rigatos GA; Kansu E; Durkovic P; Aziz Z; Al Idrissi H; Roth A; Cozma G
    Anticancer Drugs; 1997 Nov; 8(10):949-57. PubMed ID: 9436638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
    Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
    Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.
    Cascinu S; Fedeli A; Del Ferro E; Luzi Fedeli S; Catalano G
    J Clin Oncol; 1994 May; 12(5):1058-62. PubMed ID: 8164030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
    Morishima Y; Ogura M; Yoneda S; Sakai H; Tobinai K; Nishiwaki Y; Minami H; Hotta T; Ezaki K; Ohe Y; Yokoyama A; Tsuboi M; Mori K; Watanabe K; Ohashi Y; Hirashima K; Saijo N;
    Jpn J Clin Oncol; 2006 Oct; 36(10):655-61. PubMed ID: 16987908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
    Cheer SM; Wagstaff AJ
    Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
    J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
    Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
    Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
    Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
    Demetri GD; Kris M; Wade J; Degos L; Cella D
    J Clin Oncol; 1998 Oct; 16(10):3412-25. PubMed ID: 9779721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.